HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $40 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.1%

Neg 0% Neu 89.1% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $40 price target.